VA faces questions over psychedelic treatments

Lawmakers are pressing the VA on whether it has the staff, funding, and facilities to administer emerging psychedelic-assisted mental health treatments.

Exterior of the C.W. Bill Young VA Medical Center in Bay Pines, Florida.
Image credit: Timothy Westmorland / DVIDS

Bottom line up front

  • The VA estimates roughly 180,000 veterans might qualify for psychedelic therapies, but treating just 1,000 in the first year could be difficult due to resource constraints.
  • The department has identified 10 initial rollout facilities but included no dedicated funding for the program in its fiscal 2027 budget request.
  • VA officials agreed to provide Congress with a detailed staffing plan and the list of the 10 selected facilities within 30 days.

Advertisement

The Department of Veterans Affairs estimates roughly 180,000 veterans might eventually qualify for emerging psychedelic-assisted mental health therapies, but a senior official cautioned lawmakers Wednesday that treating even 1,000 patients in the first year could be a significant challenge.

During a House Veterans' Affairs subcommittee hearing, lawmakers pressed VA officials on whether the department has the necessary resources, facilities, and staff to administer the therapies. The treatments, which utilize compounds like MDMA and psilocybin, show promise for treating post-traumatic stress disorder and severe depression. Andrew Gradison, a senior adviser to the Veterans Health Administration, defended the VA's ongoing efforts.

"If we save one veteran's life next year from these treatments, it's worth it," Gradison said.

The department has already selected 10 facilities to support the initial rollout, which will handle both clinical implementation and clinician training. However, the VA has not yet publicly disclosed the locations. Officials also admitted that the fiscal 2027 budget request lacks dedicated funding for the program, though they maintained existing resources are sufficient.

Currently, approximately 2.1 million veterans receiving VA healthcare have diagnoses that include PTSD, major depressive disorder, or treatment-resistant depression. While the 180,000 patient estimate is based on early screening criteria from ongoing research, actual eligibility will depend heavily on FDA approval and its associated regulations. The VA is actively conducting 21 psychedelic-treatment studies.

These treatments demand substantial clinical resources, including preparation work, supervised dosing sessions lasting six to eight hours, and follow-up care. A recent inspector general report highlighted that 58% of reporting VA facilities are already experiencing severe psychologist shortages, sparking congressional concerns about the department’s ability to sustain the heavy workload.

Rep. Maggie Goodlander, D-N.H., questioned how the VA plans to prioritize patients if demand exceeds capacity. Gradison responded that clinical eligibility, patient safety, and medical ethics would guide all scheduling decisions.

Rep. Morgan Luttrell, R-Texas, a vocal advocate for psychedelic therapies for veterans, urged the department to get the rollout right, warning, "If you mess up this much, this goes away forever."

Gradison committed to providing Congress with a detailed staffing plan and the list of the 10 chosen facilities within 30 days.

Read the full story at Military Times

Reviewed by

Lauren Piette

Lauren Piette, Editor

Lauren Piette is a content strategist and editor at Military Brands, where she curates and polishes storytelling that informs, supports, and empowers the military community.

Darrell B. Perry

Darrell B. Perry, Creative Director

Darrell B. Perry is an award-winning media professional whose career spans photojournalism, publishing, and broadcast media.

Join our newsletter

Get the latest VeteranLife content and news.

VeteranLife Logo

©2026 VeteranLife. All rights reserved.